Today in Ostrava, the clinical evaluation of the device was officially launched as part of a clinical study aimed at demonstrating the safety of non-invasive inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI), which may precede the development of Alzheimer’s dementia.
The study connects a Czech clinical site with a top-tier Japanese scientific team and represents an important step toward moving molecular hydrogen from the realm of research into legitimate use in healthcare.
The project is led by the Czech company H2 Medical Technologies, part of the H2 Global Group.
We would like to thank all partners and teams who are part of this milestone.
You can find the article here:
https://www.metro.cz/protext/ceska-republika-v-cele-inovaci-dnes-bylo-zahajeno-klinicke-hodnoceni-pristroje-s-molekularnim-vodike.A260119_150700_metro-protext_air